Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Bio… Read more
Sernova Biotherapeutics Inc (PSH0) - Total Liabilities
Latest total liabilities as of October 2025: €25.84 Million EUR
Based on the latest financial reports, Sernova Biotherapeutics Inc (PSH0) has total liabilities worth €25.84 Million EUR as of October 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sernova Biotherapeutics Inc - Total Liabilities Trend (2022–2025)
This chart illustrates how Sernova Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sernova Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sernova Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dong-A Hwa Sung Co.Ltd
KQ:041930
|
Korea | ₩133.83 Billion |
|
Abnova Taiwan Corp
TW:4133
|
Taiwan | NT$74.25 Million |
|
MEGA International Development Co Ltd
TWO:5529
|
Taiwan | NT$3.93 Billion |
|
Engtex Group Bhd
KLSE:5056
|
Malaysia | RM729.90 Million |
|
Newegg Commerce Inc
NASDAQ:NEGG
|
USA | $258.64 Million |
|
Ladprao General Hospital Public Company Limited
BK:LPH
|
Thailand | ฿809.67 Million |
|
BEML LAND ASSETS LTD
NSE:BLAL
|
India | ₹121.00 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Sernova Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 33.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sernova Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sernova Biotherapeutics Inc (2022–2025)
The table below shows the annual total liabilities of Sernova Biotherapeutics Inc from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | €25.84 Million | +26.15% |
| 2024-10-31 | €20.48 Million | +113.55% |
| 2023-10-31 | €9.59 Million | +96.71% |
| 2022-10-31 | €4.88 Million | -- |